Back to Agenda
Pricing, Economics, Reimbursement, Market Share (PERMS) Strategy: An Interactive Holistic Approach in Rare Diseases
Session Chair(s)
Pete Mallow, PHD
Assistant Director, Health Economics, CTI Clinical Trial and Consulting, United States
Many countries incentivize orphan drug development; however, reimbursement is not assured at a viable level. This session presents a strategy to assess orphan drug development that accounts for pricing, economics, reimbursement, and market size.
Learning Objective : Define factors affecting orphan drug pricing, reimbursement, and market access; Develop familiarity with economic simulation methods; Appraise different model input values that affect key outcomes of interest.
Speaker(s)
William Irish
Vice President, Health Outcomes Research and Biostatistics, CTI Clinical Trial and Consulting Services, United States
Rare Diseases: Background and Implications for the Pricing, Economics, Reimbursement, Market Share (PERMS) Strategy
John Rizzo, PHD, MA
Professor, Economics and Preventative Medicine, Program in Public Health , Stony Brook University, United States
Economic Aspects of Pricing, Health Economics, Reimbursement, Market Share (PERMS) Strategy
Have an account?